List of therapeutic monoclonal antibodies

This is a list of therapeutic, diagnostic and preventive monoclonal antibodies, antibodies that are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies.

Types of monoclonal antibodies with other structures than naturally occurring antibodies.

The abbreviations in the column Type are as follows:

This list includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage.

Name Trade name Type Source Target Use
3F8 mab mouse GD2 neuroblastoma
8H9[1] mab mouse B7-H3 neuroblastoma, sarcoma, metastatic brain cancers
Abagovomab[2] mab mouse CA-125 (imitation) ovarian cancer
Abciximab ReoPro Fab chimeric CD41 (integrin alpha-IIb) platelet aggregation inhibitor
Abituzumab[3] mab humanized CD51 cancer
Abrilumab[4] mab human integrin α4β7 inflammatory bowel disease, ulcerative colitis, Crohn's disease
Actoxumab[5] mab human Clostridium difficile Clostridium difficile colitis
Adalimumab Humira mab human TNF-α Rheumatoid arthritis, Crohn's Disease, Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hemolytic disease of the newborn
Adecatumumab[6] mab human EpCAM prostate and breast cancer
Aducanumab[7] mab human beta-amyloid Alzheimer's disease
Afelimomab F(ab')2 mouse TNF-α sepsis
Afutuzumab[8] mab humanized CD20 lymphoma
Alacizumab pegol[9] F(ab')2 humanized VEGFR2 cancer
ALD518[10] ? humanized IL-6 rheumatoid arthritis
Alemtuzumab[11] Campath, MabCampath mab humanized CD52 Multiple sclerosis
Alirocumab[12] mab human PCSK9 hypercholesterolemia
Altumomab pentetate Hybri-ceaker mab mouse CEA colorectal cancer (diagnosis)
Amatuximab[13] mab chimeric mesothelin cancer
Anatumomab mafenatox Fab mouse TAG-72 non-small cell lung carcinoma
Anetumab ravtansine[3] mab human MSLN cancer
Anifrolumab[14] mab human interferon α/β receptor systemic lupus erythematosus
Anrukinzumab[9] (= IMA-638)[15] mab humanized IL-13 ?
Apolizumab[16] mab humanized HLA-DR ? hematological cancers
Arcitumomab CEA-Scan Fab' mouse CEA gastrointestinal cancers (diagnosis)
Ascrinvacumab[17] mab human activin receptor-like kinase 1 cancer
Aselizumab[18] mab humanized L-selectin (CD62L) severely injured patients
Atezolizumab[19] mab humanized CD274 cancer
Atinumab[20] mab human RTN4 ?
Atlizumab (= tocilizumab) Actemra, RoActemra mab humanized IL-6 receptor rheumatoid arthritis
Atorolimumab mab human Rhesus factor hemolytic disease of the newborn
Bapineuzumab[21] mab humanized beta amyloid Alzheimer's disease
Basiliximab Simulect mab chimeric CD25 (α chain of IL-2 receptor) prevention of organ transplant rejections
Bavituximab[2] mab chimeric phosphatidylserine cancer, viral infections
Bectumomab LymphoScan Fab' mouse CD22 non-Hodgkin's lymphoma (detection)
Begelomab[22] mab mouse DPP4 ?
Belimumab Benlysta, LymphoStat-B mab human BAFF non-Hodgkin lymphoma etc.
Benralizumab mab humanized CD125 asthma
Bertilimumab[18] mab human CCL11 (eotaxin-1) severe allergic disorders
Besilesomab[23] Scintimun mab mouse CEA-related antigen inflammatory lesions and metastases (detection)
Bevacizumab[11] Avastin mab humanized VEGF-A metastatic cancer, retinopathy of prematurity
Bezlotoxumab[24] mab human Clostridium difficile Clostridium difficile colitis
Biciromab FibriScint Fab' mouse fibrin II, beta chain thromboembolism (diagnosis)
Bimagrumab[25][26] mab human ACVR2B myostatin inhibitor
Bimekizumab[27] mab humanized IL17A and IL17F ?
Bivatuzumab mertansine mab humanized CD44 v6 squamous cell carcinoma
Blinatumomab BiTE mouse CD19 cancer
Blosozumab[28] mab humanized SOST osteoporosis
Bococizumab[29] mab humanized neural apoptosis-regulated proteinase 1 dyslipidemia
Brentuximab vedotin[30] mab chimeric CD30 (TNFRSF8) hematologic cancers
Briakinumab[31] mab human IL-12, IL-23 psoriasis, rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis
Brodalumab[32] mab human IL-17 inflammatory diseases
Brolucizumab[19] mab humanized VEGFA ?
Brontictuzumab[22] mab Notch 1 cancer
Canakinumab[33] Ilaris mab human IL-1? rheumatoid arthritis
Cantuzumab mertansine mab humanized mucin CanAg colorectal cancer etc.
Cantuzumab ravtansine[28] mab humanized MUC1 cancers
Caplacizumab[34] mab humanized VWF thrombotic thrombocytopenic purpura, thrombosis
Capromab pendetide Prostascint mab mouse prostatic carcinoma cells prostate cancer (detection)
Carlumab[35] mab human MCP-1 oncology/immune indications
Catumaxomab[21] Removab 3funct rat/mouse hybrid EpCAM, CD3 ovarian cancer, malignant ascites, gastric cancer
cBR96-doxorubicin immunoconjugate mab humanized Lewis-Y antigen cancer
Cedelizumab mab humanized CD4 prevention of organ transplant rejections, treatment of autoimmune diseases
Certolizumab pegol[6] Cimzia Fab' humanized TNF-α Crohn's disease
Cetuximab Erbitux mab chimeric EGFR metastatic colorectal cancer and head and neck cancer
Ch.14.18 [1] mab chimeric ??? neuroblastoma
Citatuzumab bogatox[8] Fab humanized EpCAM ovarian cancer and other solid tumors
Cixutumumab mab human IGF-1 receptor solid tumors
Clazakizumab[36] mab humanized Oryctolagus cuniculus rheumatoid arthritis
Clenoliximab mab chimeric CD4 rheumatoid arthritis
Clivatuzumab tetraxetan[37] hPAM4-Cide mab humanized MUC1 pancreatic cancer
Codrituzumab[3] mab humanized glypican 3 cancer
Coltuximab ravtansine[3] mab chimeric CD19 cancer
Conatumumab[8] mab human TRAIL-R2 cancer
Concizumab[25] mab humanized TFPI bleeding
Crenezumab[38] mab humanized 1-40-β-amyloid Alzheimer's disease
CR6261 mab human Influenza A hemagglutinin infectious disease/influenza A
Dacetuzumab[9] mab humanized CD40 hematologic cancers
Daclizumab Zenapax mab humanized CD25 (α chain of IL-2 receptor) prevention of organ transplant rejections
Dalotuzumab[39] mab humanized insulin-like growth factor I receptor cancer etc.
Dapirolizumab pegol[27] mab humanized CD40 ligand ?
Daratumumab[40] mab human CD38 (cyclic ADP ribose hydrolase) cancer
Dectrekumab[19] mab human IL-13 ?
Demcizumab[41] mab humanized DLL4 cancer
Denintuzumab mafodotin[22] mab humanized CD19 cancer
Denosumab[42] Prolia mab human RANKL osteoporosis, bone metastases etc.
Derlotuximab biotin[43] mab chimeric histone complex recurrent glioblastoma multiforme
Detumomab mab mouse B-lymphoma cell lymphoma
Dinutuximab[44] mab chimeric ganglioside GD2 neuroblastoma
Diridavumab[45] mab human hemagglutinin influenza A
Dorlimomab aritox[46] F(ab')2 mouse ? ?
Drozitumab[47] mab human DR5 cancer etc.
Duligotumab[48] mab human HER3 ?
Dupilumab[49] mab human IL4 atopic diseases
Durvalumab[50] mab human CD274 cancer
Dusigitumab[51] mab human ILGF2 cancer
Ecromeximab[16] mab chimeric GD3 ganglioside malignant melanoma
Eculizumab[16] Soliris mab humanized C5 paroxysmal nocturnal hemoglobinuria
Edobacomab mab mouse endotoxin sepsis caused by Gram-negative bacteria
Edrecolomab Panorex mab mouse EpCAM colorectal carcinoma
Efalizumab[52] Raptiva mab humanized LFA-1 (CD11a) psoriasis (blocks T-cell migration)
Efungumab[2] Mycograb scFv human Hsp90 invasive Candida infection
Eldelumab[53] mab human interferon gamma-induced protein Crohn's disease, ulcerative colitis
Elgemtumab[19] mab human ERBB3 cancer
Elotuzumab mab humanized SLAMF7 multiple myeloma
Elsilimomab mab mouse IL-6 ?
Emactuzumab[22] mab humanized CSF1R cancer
Emibetuzumab[54] mab humanized HHGFR cancer
Enavatuzumab[55] mab humanized TWEAK receptor cancer etc.
Enfortumab vedotin[56] mab human AGS-22M6 cancer expressing Nectin-4
Enlimomab pegol[57] mab mouse ICAM-1 (CD54) ?
Enoblituzumab[58] mab humanized B7-H3 cancer
Enokizumab[59] mab humanized IL9 asthma
Enoticumab[48] mab human DLL4 ?
Ensituximab[60] mab chimeric 5AC cancer
Epitumomab cituxetan[61] mab mouse episialin ?
Epratuzumab mab humanized CD22 cancer, SLE
Erlizumab[62] F(ab')2 humanized ITGB2 (CD18) heart attack, stroke, traumatic shock
Ertumaxomab[21] Rexomun 3funct rat/mouse hybrid HER2/neu, CD3 breast cancer etc.
Etaracizumab Abegrin mab humanized integrin αvβ3 melanoma, prostate cancer, ovarian cancer etc.
Etrolizumab[63] mab humanized integrin α7 β7 inflammatory bowel disease
Evinacumab[64] mab human angiopoietin 3 dyslipidemia
Evolocumab[25] mab human PCSK9 hypercholesterolemia
Exbivirumab[65] mab human hepatitis B surface antigen hepatitis B
Fanolesomab[66] NeutroSpec mab mouse CD15 appendicitis (diagnosis)
Faralimomab mab mouse interferon receptor ?
Farletuzumab mab humanized folate receptor 1 ovarian cancer
Fasinumab[67] mab human HNGF acute sciatic pain
FBTA05[68][69] Lymphomun 3funct rat/mouse hybrid CD20 chronic lymphocytic leukaemia
Felvizumab mab humanized respiratory syncytial virus respiratory syncytial virus infection
Fezakinumab[70][71][72] mab human IL-22 rheumatoid arthritis, psoriasis
Ficlatuzumab[73] mab humanized HGF cancer etc.
Figitumumab mab human IGF-1 receptor adrenocortical carcinoma, non-small cell lung carcinoma etc.
Firivumab[22] mab human influenza A virus hemagglutinin ?
Flanvotumab[74] mab human TYRP1(glycoprotein 75) melanoma
Fletikumab[75] mab human IL 20 rheumatoid arthritis
Fontolizumab[16] HuZAF mab humanized IFN-γ Crohn's disease etc.
Foralumab[76] mab human CD3 epsilon ?
Foravirumab[8] mab human rabies virus glycoprotein rabies (prophylaxis)
Fresolimumab[77] mab human TGF-β idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, cancer
Fulranumab[78] mab human NGF pain
Futuximab[48] mab chimeric EGFR ?
Galiximab mab chimeric CD80 B-cell lymphoma
Ganitumab[79] mab human IGF-I cancer
Gantenerumab[33] mab human beta amyloid Alzheimer's disease
Gavilimomab[62] mab mouse CD147 (basigin) graft versus host disease
Gemtuzumab ozogamicin Mylotarg mab humanized CD33 acute myelogenous leukemia
Gevokizumab[80] mab humanized IL-1β diabetes etc.
Girentuximab[40] Rencarex mab chimeric carbonic anhydrase 9 (CA-IX) clear cell renal cell carcinoma[81]
Glembatumumab vedotin[82][83] mab human GPNMB melanoma, breast cancer
Golimumab[65] Simponi mab human TNF-α rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis
Gomiliximab mab chimeric CD23 (IgE receptor) allergic asthma
Guselkumab[84] mab human IL23 psoriasis
Ibalizumab[33] mab humanized CD4 HIV infection
Ibritumomab tiuxetan Zevalin mab mouse CD20 non-Hodgkin's lymphoma
Icrucumab[85] mab human VEGFR-1 cancer etc.
Idarucizumab[3] mab humanized dabigatran reversal of anticoagulant effects of dabigatran
Igovomab Indimacis-125 F(ab')2 mouse CA-125 ovarian cancer (diagnosis)
IMAB362 mab human CLDN18.2 gastrointestinal adenocarcinomas and pancreatic tumor
Imalumab[22] mab human MIF cancer
Imciromab Myoscint mab mouse cardiac myosin cardiac imaging
Imgatuzumab[48] mab humanized EGFR cancer
Inclacumab[34] mab human selectin P ?
Indatuximab ravtansine[28] mab chimeric SDC1 cancer
Indusatumab vedotin[19] mab human GUCY2C cancer
Infliximab Remicade mab chimeric TNF-α rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis
Intetumumab[86][87][88] mab human CD51 solid tumors (prostate cancer, melanoma)
Inolimomab mab mouse CD25 (α chain of IL-2 receptor) graft versus host disease
Inotuzumab ozogamicin[23] mab humanized CD22 cancer
Ipilimumab[42] Yervoy mab human CD152 melanoma
Iratumumab[42] mab human CD30 (TNFRSF8) Hodgkin's lymphoma
Isatuximab[89] mab chimeric CD38 cancer
Itolizumab[76] mab humanized CD6 ?
Ixekizumab[90] mab humanized IL-17A autoimmune diseases
Keliximab mab chimeric CD4 chronic asthma
Labetuzumab[52] CEA-Cide mab humanized CEA colorectal cancer
Lambrolizumab[91] mab humanized PDCD1 antineoplastic agent
Lampalizumab[48] mab humanized CFD ?
Lebrikizumab[92] mab humanized IL-13 asthma
Lemalesomab[62] mab mouse NCA-90 (granulocyte antigen) diagnostic agent
Lenzilumab[22] mab human CSF2 ?
Lerdelimumab[11] mab human TGF beta 2 reduction of scarring after glaucoma surgery
Lexatumumab[2] mab human TRAIL-R2 cancer
Libivirumab[65] mab human hepatitis B surface antigen hepatitis B
Lifastuzumab vedotin[93] mab humanized phosphate-sodium co-transporter cancer
Ligelizumab[48][94] mab humanized IGHE severe asthma and chronic spontaneous urticaria
Lilotomab satetraxetan[19] mab mouse CD37 cancer
Lintuzumab mab humanized CD33 cancer
Lirilumab[48] mab human KIR2D ?
Lodelcizumab[25] mab humanized PCSK9 hypercholesterolemia
Lokivetmab[19] mab veterinary Canis lupus familiaris IL31 ?
Lorvotuzumab mertansine mab humanized CD56 cancer
Lucatumumab[9] mab human CD40 multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma
Lulizumab pegol[95] mab humanized CD28 autoimmune diseases
Lumiliximab[6] mab chimeric CD23 (IgE receptor) chronic lymphocytic leukemia
Lumretuzumab[22] mab humanized ERBB3 cancer
Mapatumumab[21] mab human TRAIL-R1 cancer
Margetuximab[96] mab humanized ch4D5 cancer
Maslimomab ? mouse T-cell receptor ?
Mavrilimumab[97] mab human GMCSF receptor α-chain rheumatoid arthritis
Matuzumab[18] mab humanized EGFR colorectal, lung and stomach cancer
Mepolizumab Bosatria mab humanized IL-5 asthma and white blood cell diseases
Metelimumab[66] mab human TGF beta 1 systemic scleroderma
Milatuzumab[9] mab humanized CD74 multiple myeloma and other hematological malignancies
Minretumomab mab mouse TAG-72 tumor detection (and therapy?)
Mirvetuximab soravtansine[98] mab chimeric folate receptor alpha cancer
Mitumomab mab mouse GD3 ganglioside small cell lung carcinoma
Mogamulizumab[99] mab humanized CCR4 cancer
Morolimumab mab human Rhesus factor ?
Motavizumab[2] Numax mab humanized respiratory syncytial virus respiratory syncytial virus (prevention)
Moxetumomab pasudotox[100] mab mouse CD22 cancer
Muromonab-CD3 Orthoclone OKT3 mab mouse CD3 prevention of organ transplant rejections
Nacolomab tafenatox Fab mouse C242 antigen colorectal cancer
Namilumab[20] mab human CSF2 ?
Naptumomab estafenatox[101] Fab mouse 5T4 non-small cell lung carcinoma, renal cell carcinoma
Narnatumab[102] mab human RON cancer
Natalizumab Tysabri mab humanized integrin α4 multiple sclerosis, Crohn's disease
Nebacumab mab human endotoxin sepsis
Necitumumab[103] mab human EGFR non-small cell lung carcinoma
Nemolizumab[19] mab humanized IL31RA ?
Nerelimomab mab mouse TNF-α ?
Nesvacumab[104] mab human angiopoietin 2 cancer
Nimotuzumab[42][105] Theracim, Theraloc mab humanized EGFR squamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, glioma
Nivolumab[106] mab human PD-1 cancer
Nofetumomab merpentan Verluma Fab mouse ? cancer (diagnosis)
Obiltoxaximab[107] mab chimeric Bacillus anthracis anthrax Bacillus anthracis spores
Obinutuzumab Gazyva mab humanized CD20 Chronic lymphatic leukemia
Ocaratuzumab[108] mab humanized CD20 cancer
Ocrelizumab[42] mab humanized CD20 rheumatoid arthritis, lupus erythematosus etc.
Odulimomab mab mouse LFA-1 (CD11a) prevention of organ transplant rejections, immunological diseases
Ofatumumab[21] Arzerra mab human CD20 chronic lymphocytic leukemia etc.
Olaratumab mab human PDGF-R α cancer
Olokizumab[76] mab humanized IL6 ?
Omalizumab[62] Xolair mab humanized IgE Fc region allergic asthma
Onartuzumab[109] mab humanized human scatter factor receptor kinase cancer
Ontuxizumab[110] mab chimeric/humanized TEM1 cancer
Opicinumab[111] mab human LINGO-1 multiple sclerosis
Oportuzumab monatox[103] scFv humanized EpCAM cancer
Oregovomab[66] OvaRex mab mouse CA-125 ovarian cancer
Orticumab[48] mab human oxLDL ?
Otelixizumab[9] mab chimeric/humanized CD3 diabetes mellitus type 1
Otlertuzumab[112] mab humanized CD37 cancer
Oxelumab[113] mab human OX-40 asthma
Ozanezumab[114] mab humanized NOGO-A ALS and multiple sclerosis
Ozoralizumab[115] mab humanized TNF-α inflammation
Pagibaximab[21] mab chimeric lipoteichoic acid sepsis (Staphylococcus)
Palivizumab Synagis, Abbosynagis mab humanized F protein of respiratory syncytial virus respiratory syncytial virus (prevention)
Panitumumab[65] Vectibix mab human EGFR colorectal cancer
Pankomab mab humanized tumor specific glycosylation of MUC1 ovarian cancer
Panobacumab[103] mab human Pseudomonas aeruginosa Pseudomonas aeruginosa infection
Parsatuzumab[48] mab human EGFL7 cancer
Pascolizumab[16] mab humanized IL-4 asthma
Pasotuxizumab[22] mab chimeric/humanized folate hydrolase cancer
Pateclizumab[28] mab humanized LTA TNF
Patritumab[34] mab human HER3 cancer
Pembrolizumab[116] mab humanized PDCD1 cancer etc.
Pemtumomab Theragyn ? mouse MUC1 cancer
Perakizumab[48] mab humanized IL17A arthritis
Pertuzumab Omnitarg mab humanized HER2/neu cancer
Pexelizumab[52] scFv humanized C5 reduction of side effects of cardiac surgery
Pidilizumab[117] mab humanized PD-1 cancer and infectious diseases
Pinatuzumab vedotin[25] mab humanized CD22 cancer
Pintumomab mab mouse adenocarcinoma antigen adenocarcinoma (imaging)
Placulumab[118] mab human human TNF ?
Polatuzumab vedotin[25][119] mab humanized CD79B cancer
Ponezumab[120] mab humanized human beta-amyloid Alzheimer's disease
Priliximab mab chimeric CD4 Crohn's disease, multiple sclerosis
Pritoxaximab[25] mab chimeric E. coli shiga toxin type-1 ?
Pritumumab mab human vimentin brain cancer
PRO 140 ? humanized CCR5 HIV infection
Quilizumab[34] mab humanized IGHE asthma
Tetulomab mab humanized CD37 cancer[121]
Racotumomab[103] mab mouse N-glycolylneuraminic acid cancer
Radretumab[20] mab human fibronectin extra domain-B cancer
Rafivirumab[8] mab human rabies virus glycoprotein rabies (prophylaxis)
Ralpancizumab[122] mab humanized neural apoptosis-regulated proteinase 1 dyslipidemia
Ramucirumab Cyramza mab human VEGFR2 solid tumors
Ranibizumab[6] Lucentis Fab humanized VEGF-A macular degeneration (wet form)
Raxibacumab[23] mab human anthrax toxin, protective antigen anthrax (prophylaxis and treatment)
Refanezumab[123] mab humanized myelin-associated glycoprotein recovery of motor function after stroke
Regavirumab mab human cytomegalovirus glycoprotein B cytomegalovirus infection
Reslizumab[52] mab humanized IL-5 inflammations of the airways, skin and gastrointestinal tract
Rilotumumab[124] mab human HGF solid tumors
Rinucumab[125] mab human platelet-derived growth factor receptor beta neovascular age-related macular degeneration
Rituximab MabThera, Rituxan mab chimeric CD20 lymphomas, leukemias, some autoimmune disorders
Robatumumab mab human IGF-1 receptor cancer
Roledumab[76] mab human RHD ?
Romosozumab[126] mab humanized sclerostin osteoporosis
Rontalizumab[127] mab humanized IFN-α systemic lupus erythematosus
Rovelizumab LeukArrest mab humanized CD11, CD18 haemorrhagic shock etc.
Ruplizumab[11] Antova mab humanized CD154 (CD40L) rheumatic diseases
Sacituzumab govitecan[128] mab humanized tumor-associated calcium signal transducer 2 cancer
Samalizumab[129] mab humanized CD200 cancer
Sarilumab[130] mab human IL6 rheumatoid arthritis, ankylosing spondylitis
Satumomab pendetide mab mouse TAG-72 cancer (diagnosis)
Secukinumab[131] mab human IL-17A uveitis, rheumatoid arthritis psoriasis
Seribantumab[25] mab human ERBB3 cancer
Setoxaximab[25] mab chimeric E. coli shiga toxin type-2 ?
Sevirumab ? human cytomegalovirus cytomegalovirus infection
Sibrotuzumab mab humanized FAP cancer
SGN-CD19A mab humanized CD19 acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
SGN-CD33A mab humanized CD33 Acute myeloid leukemia
Sifalimumab[132] mab humanized IFN-α SLE, dermatomyositis, polymyositis
Siltuximab mab chimeric IL-6 cancer
Simtuzumab[48] mab humanized LOXL2 fibrosis
Siplizumab[16] mab humanized CD2 psoriasis, graft-versus-host disease (prevention)
Sirukumab[133] mab human IL-6 rheumatoid arthritis
Sofituzumab vedotin[134] mab humanized CA 125 ovarian cancer
Solanezumab[103] mab humanized beta amyloid Alzheimer's disease
Solitomab[34] mab mouse EpCAM ?
Sonepcizumab[135] ? humanized sphingosine-1-phosphate choroidal and retinal neovascularization
Sontuzumab[105] mab humanized episialin ?
Stamulumab[42][105] mab human myostatin muscular dystrophy
Sulesomab LeukoScan Fab' mouse NCA-90 (granulocyte antigen) osteomyelitis (imaging)
Suvizumab[82] mab humanized HIV-1 viral infections
Tabalumab[136] mab human BAFF B-cell cancers
Tacatuzumab tetraxetan AFP-Cide mab humanized alpha-fetoprotein cancer
Tadocizumab[105] Fab humanized integrin αIIbβ3 percutaneous coronary intervention
Talizumab mab humanized IgE allergic reaction
Tanezumab[8] mab humanized NGF pain
Taplitumomab paptox[62] mab mouse CD19 cancer
Tarextumab[137] mab human Notch receptor cancer
Tefibazumab[23] Aurexis mab humanized clumping factor A Staphylococcus aureus infection
Telimomab aritox Fab mouse ? ?
Tenatumomab[9] mab mouse tenascin C cancer
Teneliximab[16] mab chimeric CD40 ?
Teplizumab[33] mab humanized CD3 diabetes mellitus type 1
Teprotumumab[138] mab human CD221 hematologic tumors
Tesidolumab[19] mab human C5 ?
TGN1412 ? humanized CD28 chronic lymphocytic leukemia, rheumatoid arthritis
Ticilimumab (= tremelimumab) mab human CTLA-4 cancer
Tildrakizumab[139] mab humanized IL23 immunologically mediated inflammatory disorders
Tigatuzumab[9] mab humanized TRAIL-R2 cancer
TNX-650 ? humanized IL-13 Hodgkin's lymphoma
Tocilizumab[6] (= atlizumab) Actemra, RoActemra mab humanized IL-6 receptor rheumatoid arthritis
Toralizumab[16] mab humanized CD154 (CD40L) rheumatoid arthritis, lupus nephritis etc.
Tosatoxumab[3] mab human Staphylococcus aureus ?
Tositumomab Bexxar ? mouse CD20 follicular lymphoma
Tovetumab[140] mab human CD140a cancer
Tralokinumab[141] mab human IL-13 asthma etc.
Trastuzumab Herceptin mab humanized HER2/neu breast cancer
TRBS07[142] Ektomab 3funct ? GD2 melanoma
Tregalizumab[20] mab humanized CD4 ?
Tremelimumab mab human CTLA-4 cancer
Trevogrumab[143] mab human growth differentiation factor 8 muscle atrophy due to orthopedic disuse and sarcopenia
Tucotuzumab celmoleukin[42][105] mab humanized EpCAM cancer
Tuvirumab ? human hepatitis B virus chronic hepatitis B
Ublituximab[20] mab chimeric MS4A1 cancer
Ulocuplumab[144] mab human C-X-C chemokine receptor type 4 hematologic malignancies
Urelumab[145] mab human 4-1BB cancer etc.
Urtoxazumab[6] mab humanized Escherichia coli diarrhoea caused by E. coli
Ustekinumab[8] Stelara mab human IL-12, IL-23 multiple sclerosis, psoriasis, psoriatic arthritis
Vandortuzumab vedotin[19] mab humanized STEAP1 cancer
Vantictumab[146] mab human Frizzled receptor cancer
Vanucizumab[22] mab humanized angiopoietin 2 cancer
Vapaliximab[16] mab chimeric AOC3 (VAP-1) ?
Varlilumab[147] mab human CD27 ?
Vatelizumab[28] mab humanized ITGA2 ?
Vedolizumab mab humanized integrin α4β7 Crohn's disease, ulcerative colitis
Veltuzumab[9] mab humanized CD20 non-Hodgkin's lymphoma
Vepalimomab mab mouse AOC3 (VAP-1) inflammation
Vesencumab[20] mab human NRP1 ?
Visilizumab[62] Nuvion mab humanized CD3 Crohn's disease, ulcerative colitis
Volociximab[21] mab chimeric integrin α5β1 solid tumors
Vorsetuzumab mafodotin[148] mab humanized CD70 cancer
Votumumab HumaSPECT mab human tumor antigen CTAA16.88 colorectal tumors
Zalutumumab[21] HuMax-EGFr mab human EGFR squamous cell carcinoma of the head and neck
Zanolimumab[6] HuMax-CD4 mab human CD4 rheumatoid arthritis, psoriasis, T-cell lymphoma
Zatuximab[48] mab chimeric HER1 cancer
Ziralimumab[62] mab human CD147 (basigin) ?
Zolimomab aritox mab mouse CD5 systemic lupus erythematosus, graft-versus-host disease

References

  1. 1 2 "United Therapeutics 10-K report". Retrieved 5 November 2011.
  2. 1 2 3 4 5 World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 95" (PDF). WHO Drug Information 20 (2).
  3. 1 2 3 4 5 6 World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information 27 (2).
  4. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Abrilumab" (PDF). American Medical Association.
  5. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Actoxumab" (PDF). American Medical Association.
  6. 1 2 3 4 5 6 7 World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 90" (PDF). WHO Drug Information 18 (1).
  7. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Aducanumab" (PDF). American Medical Association.
  8. 1 2 3 4 5 6 7 World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 99" (PDF). WHO Drug Information 22 (2).
  9. 1 2 3 4 5 6 7 8 9 World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98" (PDF). WHO Drug Information 21 (4).
  10. ↑ "BMS Shells Out $85M Up Front for Alder’s Mid-Stage Rheumatoid Arthritis Antibody". Genetic Engineering & Biotechnology News. 10 November 2009.
  11. 1 2 3 4 World Health Organization (2000). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 83" (PDF). WHO Drug Information 14 (2).
  12. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Alirocumab" (PDF). American Medical Association.
  13. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Amatuximab" (PDF). American Medical Association.
  14. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Anifrolumab" (PDF). American Medical Association.
  15. ↑ "Wyeth.com | Complete Project Listing". Wyeth. 2008. Archived from the original on June 12, 2008. Retrieved November 19, 2008.
  16. 1 2 3 4 5 6 7 8 9 World Health Organization (2002). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 87" (PDF). WHO Drug Information 16 (2).
  17. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ascrinvacumab" (PDF). American Medical Association.
  18. 1 2 3 World Health Organization (2003). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 88" (PDF). WHO Drug Information 17 (1).
  19. 1 2 3 4 5 6 7 8 9 10 World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information 28 (4).
  20. 1 2 3 4 5 6 World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information 24 (4).
  21. 1 2 3 4 5 6 7 8 World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 93" (PDF). WHO Drug Information 19 (2).
  22. 1 2 3 4 5 6 7 8 9 10 World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information 28 (2).
  23. 1 2 3 4 World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 92" (PDF). WHO Drug Information 18 (4).
  24. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Bezlotoxumab" (PDF). American Medical Association.
  25. 1 2 3 4 5 6 7 8 9 World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108" (PDF). WHO Drug Information 26 (4).
  26. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Bimagrumab" (PDF). American Medical Association.
  27. 1 2 World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information 27 (4).
  28. 1 2 3 4 5 World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information 25 (2).
  29. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Bococizumab" (PDF). American Medical Association.
  30. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Brentuximab vedotin" (PDF). American Medical Association.
  31. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Briakinumab" (PDF). American Medical Association.
  32. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Brodalumab" (PDF). American Medical Association.
  33. 1 2 3 4 World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 97" (PDF). WHO Drug Information 21 (2).
  34. 1 2 3 4 5 World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information 25 (4).
  35. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Carlumab" (PDF). American Medical Association.
  36. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Clazakizumab" (PDF). American Medical Association.
  37. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Yttrium Y90 clivatuzumab tetraxetan" (PDF). American Medical Association.
  38. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Crenezumab" (PDF). American Medical Association.
  39. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Dalotuzumab" (PDF). American Medical Association.
  40. 1 2 World Health Organization (2009). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 101" (PDF). WHO Drug Information 23 (2).
  41. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Demcizumab" (PDF). American Medical Association.
  42. 1 2 3 4 5 6 7 World Health Organization (2005). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 94" (PDF). WHO Drug Information 19 (4).
  43. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Iodine I 131 Derlotuximab biotin" (PDF). American Medical Association.
  44. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Dinutuximab" (PDF). American Medical Association.
  45. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Diridavumab" (PDF). American Medical Association.
  46. ↑ World Health Organization (1991). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 66" (PDF). WHO Drug Information 5 (4).
  47. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Drozitumab" (PDF). American Medical Association.
  48. 1 2 3 4 5 6 7 8 9 10 11 12 World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information 26 (2).
  49. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Dupilumab" (PDF). American Medical Association.
  50. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Durvalumab" (PDF). American Medical Association.
  51. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Dusigitumab" (PDF). American Medical Association.
  52. 1 2 3 4 World Health Organization (2001). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 85" (PDF). WHO Drug Information 15 (2).
  53. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Eldelumab" (PDF). American Medical Association.
  54. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Emibetuzumab" (PDF). American Medical Association.
  55. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Enavatuzumab" (PDF). American Medical Association.
  56. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Enfortumab Vedotin" (PDF). American Medical Association.
  57. ↑ World Health Organization (1997). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77" (PDF). WHO Drug Information 11 (2).
  58. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Enoblituzumab" (PDF). American Medical Association.
  59. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Enokizumab" (PDF). American Medical Association.
  60. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ensituximab" (PDF). American Medical Association.
  61. ↑ World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 51" (PDF). WHO Drug Information 18 (1).
  62. 1 2 3 4 5 6 7 World Health Organization (2000). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 84" (PDF). WHO Drug Information 14 (4).
  63. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Etrolizumab" (PDF). American Medical Association.
  64. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Evinacumab" (PDF). American Medical Association.
  65. 1 2 3 4 World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 91" (PDF). WHO Drug Information 18 (2).
  66. 1 2 3 World Health Organization (2002). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 86" (PDF). WHO Drug Information 16 (12).
  67. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fasinumab" (PDF). American Medical Association.
  68. ↑ Buhmann, R; Stanglmaier, M; Yang, T; Faltin, M; Bund, D; Lindhofer, H; Kolb, HJ; et al. (2008). "Immunotherapy of recurrent B–cell malignancies after allo SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion". Bone Marrow Transplantation 43 (5): 383–397. doi:10.1038/bmt.2008.323. PMID 18850012. |first2= missing |last2= in Authors list (help)
  69. ↑ Boehrer, S; Mueller, Tina; Atz, Judith; Chow, Kai Uwe; et al. (2011). "Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanisms". Anti-Cancer Drugs 12 (10): 3085–3091. doi:10.1097/CAD.0b013e328344887f. |first2= missing |last2= in Authors list (help)
  70. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab" (PDF). American Medical Association.
  71. ↑ Clinical trial number NCT00883896 for "Study to Evaluate the Safety and Efficacy of ILV-094 in Subjects With Rheumatoid Arthritis" at ClinicalTrials.gov
  72. ↑ Clinical trial number NCT00563524 for "Study Evaluating the Safety and Tolerability of ILV-094 in Subjects With Psoriasis" at ClinicalTrials.gov
  73. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab" (PDF). American Medical Association.
  74. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Flanvotumab" (PDF). American Medical Association.
  75. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fletikumab" (PDF). American Medical Association.
  76. 1 2 3 4 World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information.
  77. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fresolimumab" (PDF). American Medical Association.
  78. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fulranumab" (PDF). American Medical Association.
  79. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab" (PDF). American Medical Association.
  80. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Gevokizumab" (PDF). American Medical Association.
  81. ↑ http://www.prnewswire.com/news-releases/prometheus-obtains-exclusive-us-commercialization-rights-for-rencarex-121075044.html
  82. 1 2 World Health Organization (2009). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 102" (PDF). WHO Drug Information 23 (4).
  83. ↑ NCI Drug Dictionary: Glemtumumab vedotin
  84. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Guselkumab" (PDF). American Medical Association.
  85. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab" (PDF). American Medical Association.
  86. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab" (PDF). American Medical Association.
  87. ↑ Clinical trial number NCT00537381 for "A Study of the Safety and Effectiveness of CNTO 95 in Patients With Metastatic Hormone Refractory Prostate Cancer" at ClinicalTrials.gov
  88. ↑ Clinical trial number NCT00246012 for "A Study of the Safety and Efficacy CNTO 95 in Subjects With Advanced Melanoma" at ClinicalTrials.gov
  89. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Isatuximab" (PDF). American Medical Association.
  90. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ixekizumab" (PDF). American Medical Association.
  91. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Lambrolizumab" (PDF). American Medical Association.
  92. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Lebrikizumab" (PDF). American Medical Association.
  93. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Lifastuzumab Vedotin" (PDF). American Medical Association.
  94. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ligelizumab" (PDF). American Medical Association.
  95. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Lulizumab Pegol" (PDF). American Medical Association.
  96. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Margetuximab" (PDF). American Medical Association.
  97. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Mavrilimumab" (PDF). American Medical Association.
  98. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Mirvetuximab Sorevtansine" (PDF). American Medical Association.
  99. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Mogamulizumab" (PDF). American Medical Association.
  100. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Moxetumomab Pasudotox" (PDF). American Medical Association.
  101. ↑ World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 96" (PDF). WHO Drug Information 20 (4).
  102. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Narnatumab" (PDF). American Medical Association.
  103. 1 2 3 4 5 World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 100 (prepublication copy)" (PDF). WHO Drug Information.
  104. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Nesvacumab" (PDF). American Medical Association.
  105. 1 2 3 4 5 World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 56" (PDF). WHO Drug Information 20 (3).
  106. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Nivolumab" (PDF). American Medical Association.
  107. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Obiltoxaximab" (PDF). American Medical Association.
  108. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ocaratuzumab" (PDF). American Medical Association.
  109. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab" (PDF). American Medical Association.
  110. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ontuxizumab" (PDF). American Medical Association.
  111. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Opicinumab" (PDF). American Medical Association.
  112. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Otlertuzumab" (PDF). American Medical Association.
  113. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Oxelumab" (PDF). American Medical Association.
  114. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ozanezumab" (PDF). American Medical Association.
  115. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ozoralizumab" (PDF). American Medical Association.
  116. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Pembrolizumab" (PDF). American Medical Association.
  117. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Pidilizumab" (PDF). American Medical Association.
  118. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Placulumab" (PDF). American Medical Association.
  119. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Polatuzumab Vedotin" (PDF). American Medical Association.
  120. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab" (PDF). American Medical Association.
  121. ↑ Jostein Dahle, Ada H. V. Repetto-Llamazares, Camilla S. Mollatt, Katrine B. Melhus, Oyvind S. Bruland, Arne Kolstad & Roy H. Larsen (January 2013). "Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma". Anticancer research 33 (1): 85–95. PMID 23267131.
  122. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ralpancizumab" (PDF). American Medical Association.
  123. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Refanezumab" (PDF). American Medical Association.
  124. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Rilotumumab" (PDF). American Medical Association.
  125. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Rinucumab" (PDF). American Medical Association.
  126. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Romosozumab" (PDF). American Medical Association.
  127. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Rontalizumab" (PDF). American Medical Association.
  128. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sacituzumab Govitecan" (PDF). American Medical Association.
  129. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab" (PDF). American Medical Association.
  130. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sarilumab" (PDF). American Medical Association.
  131. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Secukinumab" (PDF). American Medical Association.
  132. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab" (PDF). American Medical Association.
  133. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab" (PDF). American Medical Association.
  134. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sofituzumab Vedotin" (PDF). American Medical Association.
  135. ↑ Xie, B.; Shen, J.; Dong, A.; Rashid, A.; Stoller, G.; Campochiaro, P. A. (2009). "Blockade of Sphingosine-1-phosphate Reduces Macrophage Influx and Retinal and Choroidal Neovascularization". Journal of Cellular Physiology 218 (1): 192–198. doi:10.1002/jcp.21588. PMC 2905312. PMID 18781584.
  136. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Tabalumab" (PDF). American Medical Association.
  137. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Tarextumab" (PDF). American Medical Association.
  138. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Teprotumumab" (PDF). American Medical Association.
  139. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Tildrakizumab" (PDF). American Medical Association.
  140. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Tovetumab" (PDF). American Medical Association.
  141. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Tralokinumab" (PDF). American Medical Association.
  142. ↑ Ruf, P; Ellwart, J; Wosch, S; Kusterer, E; Lindhofer, H; et al. (2004). "Two new trifunctional antibodies for the therapy of human malignant melanoma". International Journal of Cancer 108 (5): 725–732. doi:10.1002/ijc.11630. PMID 14696099. |first2= missing |last2= in Authors list (help)
  143. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Trevogrumab" (PDF). American Medical Association.
  144. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ulocuplumab" (PDF). American Medical Association.
  145. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Urelumab" (PDF). American Medical Association.
  146. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Vantictumab" (PDF). American Medical Association.
  147. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Varlilumab" (PDF). American Medical Association.
  148. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Vorsetuzumab Mafodotin" (PDF). American Medical Association.
This article is issued from Wikipedia - version of the Monday, February 15, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.